Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer

ABSTRACT: Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer

PROVIDER: PRJNA778066 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [array]

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [array]

| PRJNA776250 | ENA

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

| PRJNA778073 | ENA

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [RNA-Seq]

Project description:Here we describe the clinical and biological activity of guadecitabine, a second generation HMA, given in a low dose as a priming strategy before pembrolizumab, a humanized anti-PD1 antibody in a clinical trial for patients with recurrent, platinum resistant ovarian cancer. The methylomic and transcriptomic effects of the combination demonstrate readily activation of the anti-tumor immunity. High dimensional immune profiling of periferal mononuclear cells (PBMCs) and tumor biopsies obtained before and after treatment show distinct immune profiles and tissue architectural features associated with clinical benefit. Our study provides an in-depth view of the immune milieu of platinum resistant ovarian cancer and of the effects of the combination of HMAs and pembrolizumab on the interactions between immune cell populations and tumor cells.

2022-06-20 | GSE188249 | GEO

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer [methylation array]

2022-06-20 | GSE186825 | GEO

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-06-20 | GSE188250 | GEO

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

| PRJNA765317 | ENA

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

Project description:Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

| PRJNA683080 | ENA

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [RNA-Seq]

| PRJNA765320 | ENA

Human fetal immunity and microbial priming during early development

Project description:Human fetal immunity and microbial priming during early development

| PRJNA716244 | ENA

Dnase1l3 enhances antitumor immunity and suppresses tumor progression

Project description:Dnase1l3 enhances antitumor immunity and suppresses tumor progression

| PRJNA803220 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data